Log in

RegulatoryBusinessLine

USFDA issues 7 observations to NATCO Pharma

Negative-678 sources

GreyOak summary

NATCO Pharma Limited received seven observations from the USFDA following an inspection of its Hyderabad manufacturing facility. The regulator cited conditions that may constitute violations of laws. The company describes the issues as procedural and is confident in addressing them within stipulated timelines.

What it affects

Source

Reported by BusinessLine

  • Business Today
  • BusinessLine
  • Economic Times
  • Economic Times
  • Economic Times
  • CNBC-TV18
  • Business Standard
  • BusinessLine

More Natco Pharma news

All Natco Pharma news →

The company today

Price, day change, sector and market cap of the companies this story names
CompanyPriceDay changeSectorMarket cap
Natco PharmaNATCOPHARM · NSE₹814.30−0.93%Healthcare₹15,974 crore

Prices as of ; the last session's close when the market is shut. Research, not investment advice.

Latest market news

News Intelligence →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy